CAR-T Cell Therapy marketanalysis, industry share, size, strategies and forecastPosted by akshayparmar on August 13th, 2018 The latest market report published by Credence Research, Inc. “CAR-T Cell Therapy Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 expanding at a CAGR of 51.1% from 2018 to 2026. Market Insights The CAR-T cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The diagnosis of acute ALL is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. World Health Organization guidelines have postulated that acute lymphocytic leukemia can be prevented up to a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR T cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications. CD19 antigens as CAR T cell therapy for the treatment of B cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL. Geographically, North America dominated the CAR-T cell therapy market due to approval of two CAR-T cell therapy candidates in the region. Moreover, rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the CAR-T cells therapy market. Moreover, the domicile of pharmaceutical companies pioneering in CAR-T cell therapy further increases the dominance of United States. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the growth of CAR-T cell therapy in Europe and Asia Pacific. However, penetration of CAR-T cell therapy within low and middle income economies are primarily hampered owing to the unavailability of suitable healthcare infrastructure and the lack of disposable income for such premium priced therapeutic options. The major pharmaceutical players actively engaged in the CAR-T cell therapy market are Gilead Sciences, Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others. Key Market Movements:
Request Sample: https://www.credenceresearch.com/sample-request/58970 About Us Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task. Contact Us: Credence Research Inc. Toll Free(US/CANADA): +1-800-361-8290
Like it? Share it! More by this author |